Fintel reports that on March 13, 2025, HC Wainwright & Co. initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

H.C. Wainwright initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $10 price target Perspective is a clinical-stage ...

Shares of Core Scientific Inc. (CORZ) gained almost 8% in Tuesday’s regular session and extended gains during after-hours ...

Stock analysts at HC Wainwright reduced their FY2029 earnings estimates for Oncolytics Biotech in a research note issued on ...

The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...

H.C. Wainwright analyst Scott Buck lowered the firm’s price target on AudioEye (AEYE) to $22 from $37 and keeps a Buy rating on the shares post ...

Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision ...

Equities researchers at HC Wainwright issued their FY2026 earnings estimates for Aquestive Therapeutics in a research note ...

Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate ...

Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...

Fintel reports that on March 5, 2025, HC Wainwright & Co. initiated coverage of Intellia Therapeutics (LSE:0JBU) with a Buy recommendation. There are 572 funds or institutions reporting positions ...